Alector Inc. Stock News

A year ago Passage Bio launched with $115.5 million and plans to advance a handful of gene therapies discovered at the University of Pennsylvania. Now the

Alector, Inc. (ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the closing of its previously announced underwritten public offering of 9,602,500 shares of it

- Total gross proceeds from the offering to Alector are approximately $240 million

Alector Inc (NASDAQ:ALEC) saw unusually-strong trading volume on Friday . Approximately 26,062 shares traded hands during trading, a decline of 94% from the previous session’s volume of 440,545 shar

Alector (NASDAQ:ALEC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday, Zacks.com reports. According to Zacks, “Alector Inc.

Alector Inc (NASDAQ:ALEC) shares hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $28.00 and last traded at $26.75, with a volume of 53606 shares traded. The s

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 30) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (

Alector, Inc. (ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the underwriters fully exercised their option to purchase an additional 1,252,500 shares

Total gross proceeds from the offering to Alector, including from the sale of the additional shares, are expected to be approximately $240 million

NEW YORK, Jan 30 (IFR) -

Alector, Inc. (ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an upsized underwritten public offering of 8,350,000 shares of its common stock

Public Offering of 8,350,000 Shares of Common Stock for Gross Proceeds of Approximately $208 Million

NEW YORK, Jan 29 (IFR) -

(Adds Live Nation Entertainment CB.)

(Corrects headline)